TY  - JOUR
AU  - Spohn, Simon K B
AU  - Birkenmaier, Viktoria
AU  - Ruf, Juri
AU  - Mix, Michael
AU  - Sigle, August
AU  - Haehl, Erik
AU  - Adebahr, Sonja
AU  - Sprave, Tanja
AU  - Gkika, Eleni
AU  - Rühle, Alexander
AU  - Nicolay, Nils H
AU  - Kirste, Simon
AU  - Grosu, Anca L
AU  - Zamboglou, Constantinos
TI  - Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer.
JO  - Frontiers in oncology
VL  - 12
SN  - 2234-943X
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2022-01343
SP  - 898774
PY  - 2022
AB  - The National Comprehensive Cancer Network recommends external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) as the preferred treatment option for newly diagnosed node-positive (cN1) prostate cancer (PCa) patients. However, implementation of positron emission tomography targeting prostate-specific membrane antigen (PSMA-PET) in the staging of primary PCa patients has a significant impact on RT treatment concepts. This study aims to evaluate outcomes and their respective risk factors on patients with PSMA-PET-based cN1 and/or cM1a PCa receiving primary RT and ADT.Forty-eight patients with cN0 and/or cM1a PCa staged by [18F]PSMA-1007-PET (n = 19) or [68Ga]PSMA-11-PET (n = 29) were retrospectively included. All patients received EBRT to the pelvis ± boost to positive nodes, followed by boost to the prostate. The impact of different PET-derived characteristics such as maximum standard uptake value (SUVmax) and number of PET-positive lymph nodes on biochemical recurrence-free survival (BRFS) (Phoenix criteria) and metastasis-free survival (MFS) was determined using Kaplan-Meier and Cox proportional hazard regression analyses.Median follow-up was 24 months. Median initial serum prostate-specific antigen was 20.2 ng/ml (IQR 10.2-54.2). Most patients had cT stage ≥ 3 (63
KW  - PSMA-PET/CT (Other)
KW  - lymph node positive (Other)
KW  - personalization (Other)
KW  - prostate cancer (Other)
KW  - radiotherapy (Other)
KW  - risk factors (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:35747822
C2  - pmc:PMC9209705
DO  - DOI:10.3389/fonc.2022.898774
UR  - https://inrepo02.dkfz.de/record/180464
ER  -